Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Each treatment cycle is 28 days. You will receive brentuximab alone on Day 1 and 15 of the first cycle (lead-in cycle). After cycle 1, you will receive brentuximab combined with AVD on Day 1 and 15 for 4-6 cycles, depending on your response to therapy. Brentuximab and AVD will be given to you by intravenous infusion (IV). The following test and procedures will be performed on Days 1 and 15 of each cycle: * Review of any side effects you have experienced and all medications you are taking * Performance Status * Physical exam and vital signs * Routine blood tests * Questionnaire to evaluate symptoms of neuropathy * Research blood sample to look at markers to see how your body is responding to study medication * PET-CT scan prior to completing cycle 2 of combination brentuximab/AVD After the final dose of the study drug: The following assessments will be performed within one month of your last dose of study medication: * Review of any side effects you have experienced and all medications you are taking * Performance Status * Physical exam and vital signs * Routine blood tests * Questionnaire to evaluate symptoms of neuropathy * Research blood sample to look at markers to see how your body is responding to study medication * PET-CT scan Follow up will include the following * Review of any side effects you have experienced and all medications you are taking * Performance Status * Review and Physical exam * Routine blood tests * Questionnaire to evaluate symptoms of neuropathy * CT scans